Oncology and Cancer Immunotherapy

Partnering opportunities we are looking for:

  • Oncogenic drivers

  • Synthetic lethality

  • Adaptive and innate immunity

  • Neoantigens

  • Stromal biology

  • Cell therapies

Example partnerships

Our ultimate vision is to prevent and provide cures for cancer in all its forms. Because no single intervention is likely to achieve this goal, we seek to comprehensively understand the disease, its complexities and its impact on patients.

We have the broadest and most diverse pipeline in oncology with more than 20 immunotherapy molecules. Since 2011, we have introduced 18 oncology medicines. All our efforts are linked by exploring therapeutic combinations and by a commitment to pursuing personalized medicines.

Your dedicated partnering leads in Oncology

Patrick Schleck
Head of Oncology, Pharma Partnering
Zineb El Fajoui
Search & Evaluation Lead Oncology, Pharma Partnering

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

Contact our Pharma Partnering Team

Interested in partnering with us?

More stories

See all stories

More Pharma partnering areas

View all areas

Discover more